Research progress of indole compounds with potential antidiabetic activity

Y Zhu, J Zhao, L Luo, Y Gao, H Bao, P Li… - European Journal of …, 2021 - Elsevier
New types of antidiabetic agents are continually needed with diabetes becoming the
epidemic in the world. Indole alkaloids play an important role in natural products owing to …

DYRK1A inhibitors for disease therapy: Current status and perspectives

T Liu, Y Wang, J Wang, C Ren, H Chen… - European journal of …, 2022 - Elsevier
Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a conserved
protein kinase that plays essential roles in various biological processes. It is located in the …

Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) in human disease, an overview

MF Lindberg, L Meijer - International Journal of Molecular Sciences, 2021 - mdpi.com
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRK1A, 1B, 2-4) and cdc2-
like kinases (CLK1-4) belong to the CMGC group of serine/threonine kinases. These protein …

Pharmacological effects of harmine and its derivatives: a review

L Zhang, D Li, S Yu - Archives of pharmacal research, 2020 - Springer
Harmine is isolated from the seeds of the medicinal plant, Peganum harmala L., and has
been used for thousands of years in the Middle East and China. Harmine has many …

Comparative efficacy and selectivity of pharmacological inhibitors of DYRK and CLK protein kinases

MF Lindberg, E Deau, J Arfwedson… - Journal of medicinal …, 2023 - ACS Publications
Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases
(CLKs) play a large variety of cellular functions and are involved in several diseases …

DYRK1A inhibitors as potential therapeutics for β-cell regeneration for diabetes

K Kumar, C Suebsuwong, P Wang… - Journal of Medicinal …, 2021 - ACS Publications
According to the World Health Organization (WHO), 422 million people are suffering from
diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose …

Small-molecule kinase inhibitors for the treatment of nononcologic diseases

Z Xie, X Yang, Y Duan, J Han… - Journal of medicinal …, 2021 - ACS Publications
Great successes have been achieved in developing small-molecule kinase inhibitors as
anticancer therapeutic agents. However, kinase deregulation plays essential roles not only …

β-Carboline as a privileged scaffold for multitarget strategies in Alzheimer's disease therapy

A Beato, A Gori, B Boucherle… - Journal of Medicinal …, 2021 - ACS Publications
The natural β-carboline alkaloids display similarities with neurotransmitters that can be
favorably exploited to design bioactive and bioavailable drugs for Alzheimer's disease (AD) …

Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease

W Liu, X Liu, L Tian, Y Gao, W Liu, H Chen… - European Journal of …, 2021 - Elsevier
Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease,
characterized by irreversible cognitive impairment, memory loss and behavioral …

Function and inhibition of DYRK1A: emerging roles of treating multiple human diseases

Y Yang, X Fan, Y Liu, D Ye, C Liu, H Yang, Z Su… - Biochemical …, 2023 - Elsevier
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is an evolutionarily
conserved protein kinase and the most studied member of the Dual-specificity tyrosine …